THE PIPELINE
Advancing the first
Fas Ligand–blocking antibody in the clinic
M3T01 is a first-in-class fully human IgG4/Kappa monoclonal antibody that binds fas ligand (FasL) with picomolar affinity and potently inhibits FasL-mediated apoptosis of T cells.
TRIAL
Accelerating our progress to market viability
A phase I clinical trial is currently underway (NCT06719362) evaluating M3T01 in patients with advanced solid tumors. M3T01 is being tested as a single agent and in combination with pembrolizumab and other cancer therapies.
What'S NEXT
Partnering to Expand the Potential of FasL Blockade
Gamma Biotherapeutics is actively seeking investors and collaborators to advance M3T01 and explore new indications where protecting T cells could redefine treatment outcomes.
Co-Development Opportunities
We welcome partnerships in solid tumors, hematologic malignancies, and combination immunotherapies where FasL blockade may enhance therapeutic efficacy and durability.
